Agency Information Collection Activities; Proposed Collection; Comment Request; Recall Regulations, 31696-31697 [E8-12339]
Download as PDF
31696
Federal Register / Vol. 73, No. 107 / Tuesday, June 3, 2008 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0314]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Recall Regulations
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
FDA’s recall regulations and provides
guidance to manufacturers on recall
responsibilities.
DATES: Submit written or electronic
comments on the collection of
information by August 4, 2008.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Berbakos, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
1482.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
FDA Recall Regulations—21 CFR Part 7
(OMB Control Number 0910–0249)—
Extension
Section 701 of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 371) and 21
CFR part 7, subpart C, set forth the
recall regulations (guidelines) and
provides guidance to manufacturers on
recall responsibilities. The guidelines
apply to all FDA regulated products
(i.e., food, including animal feed; drugs,
including animal drugs; medical
devices, including in vitro diagnostic
products; cosmetics; and biological
products intended for human use).
These responsibilities include
development of a recall strategy that
requires time by the firm to determine
the actions or procedures required to
manage the recall (21 CFR 7.42);
providing FDA with complete details of
the recall including reason(s) for the
removal or correction, risk evaluation,
quantity produced, distribution
information, firm’s recall strategy, a
copy of any recall communication(s),
and a contact official (21 CFR 7.46);
notifying direct accounts of the recall,
providing guidance regarding further
distribution, giving instructions as to
what to do with the product, providing
recipients with a ready means of
reporting to the recalling firm (21 CFR
7.49); submitting periodic status reports
so that FDA may assess the progress of
the recall. Status report information may
be determined by, among other things
evaluation return reply cards,
effectiveness checks and product
returns (21 CFR 7.53); and providing the
opportunity for a firm to request in
writing that FDA terminate the recall
(21 CFR 7.55).
A search of the FDA database was
performed to determine the number of
recalls that took place during fiscal year
2007. The resulting number of recalls
from this database search (2,166) is used
in estimating the current annual
reporting burden for this report. FDA
estimates the total annual industry
burden to collect and provide the
previous information to 216,600 burden
hours.
The following table is a summary of
the estimated annual burden hours for
recalling firms (manufacturers,
processors, and distributors) to comply
with the voluntary reporting
requirements of FDA’s recall
regulations.
Recognizing that there may be a vast
difference in the information collection
and reporting time involved in different
recalls of FDA’s regulated products,
FDA estimates on average the burden of
collection for recall information to be as
follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 CFR Section
Annual Frequency
per
Response
Total Annual
Responses
Hours Per
Response
Total Hours
ebenthall on PRODPC60 with NOTICES
Recall Strategy 7.42
2,166
1
2,166
20
43,320
Firm Initiated Recall and Recall Communications 7.46 and 7.49
2,166
1
2,166
30
64,980
VerDate Aug<31>2005
14:18 Jun 02, 2008
Jkt 214001
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
E:\FR\FM\03JNN1.SGM
03JNN1
31697
Federal Register / Vol. 73, No. 107 / Tuesday, June 3, 2008 / Notices
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1—Continued
Annual Frequency
per
Response
No. of
Respondents
21 CFR Section
Total Annual
Responses
Hours Per
Response
Total Hours
Recall Status Reports and Follow-up
7.53
2,166
4
8,664
10
86,640
Termination of a Recall 7.55(b)
2,166
1
2,166
10
21,660
Total
1 There
216,600
are no capital costs or operating and maintenance costs associated with this collection of information.
The annual reporting burdens are
explained as follows:
accepted by FDA only through FDMS at
https://www.regulations.gov.
I. Reporting
Dated: May 27, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–12339 Filed 6–2–08; 8:45 am]
A. Recall Strategy
Request firms develop a recall strategy
including provision for public warnings
and effectiveness checks. Under this
portion of the collection of information,
the agency estimates it will receive
2,166 responses annually.
B. Firm Initiated Recall and Recall
Communications
Request firms voluntarily remove or
correct foods and drugs (human or
animal), cosmetics, medical devices,
and biologicals to immediately notify
the appropriate FDA district office of
such actions. The firm is to provide
complete details of the recall reason,
risk evaluation, quantity produced,
distribution information, firms’ recall
strategy and a contact official as well as
requires firms to notify their direct
accounts of the recall and to provide
recipients with a ready means of
reporting to the recalling firm. Under
these portions of the collection of
information, the agency estimates it will
receive 2,166 responses annually for
each.
C. Recall Status Reports
Request that recalling firms provide
periodic status reports so the FDA can
ascertain the progress of the recall. This
collection of information will generate
approximately 8,664 responses
annually.
ebenthall on PRODPC60 with NOTICES
D. Termination of a Recall
Provide the firms an opportunity to
request in writing that FDA end the
recall. The agency estimates it will
receive 2,166 responses annually.
Please note that on January 15, 2008,
the FDA Division of Dockets
Management Web site transitioned to
the Federal Dockets Management
System (FDMS). FDMS is a
Government-wide, electronic docket
management system. Electronic
comments or submissions will be
VerDate Aug<31>2005
14:18 Jun 02, 2008
Jkt 214001
Dated: May 27, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–12300 Filed 6–2–08; 8:45 am]
BILLING CODE 4160–01–S
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Food and Drug Administration
[Docket No. FDA–2007–E–0458 (formerly
Docket No. 2007E–0144) and Docket No.
FDA–2007–E–0460 (formerly Docket No.
2007E–0176)]
[Docket No. FDA–2007–E–0335] (formerly
Docket No. 2007E–0133) and [Docket No.
FDA–2007–E–0227] (formerly Docket No.
2007E–0148)
Determination of Regulatory Review
Period for Purposes of Patent
Extension; VEREGEN
Determination of Regulatory Review
Period for Purposes of Patent
Extension; TYZEKA; Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
SUMMARY: The Food and Drug
Administration (FDA) is correcting a
notice that appeared in the Federal
Register of May 15, 2008 (73 FR 28119),
announcing FDA’s determination of the
regulatory review period for TYZEKA.
The document published with an
incorrect docket number. This
document corrects that error.
FOR FURTHER INFORMATION CONTACT:
Joyce Strong, Office of Policy, Planning
and Preparedness (HF–27), Food and
Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
7630.
In FR Doc.
E8–10857, published on May 15, 2008
(73 FR 28119), the following correction
is made:
On page 28119, in the third column,
in the Docket No. heading, ‘‘Docket No.
FDA–2007–E–0035’’ is corrected to read
‘‘Docket No. FDA–2007–E–0335’’.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) has determined
the regulatory review period for
VEREGEN and is publishing this notice
of that determination as required by
law. FDA has made the determination
because of the submission of
applications to the Director of Patents
and Trademarks, Department of
Commerce, for the extension of patents
which claim that human drug product.
ADDRESSES: Submit written comments
and petitions to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg 51,
rm. 6222, Silver Spring, MD 20993–
0002, 301–796–3602.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98–
417) and the Generic Animal Drug and
Patent Term Restoration Act (Public
Law 100–670) generally provide that a
E:\FR\FM\03JNN1.SGM
03JNN1
Agencies
[Federal Register Volume 73, Number 107 (Tuesday, June 3, 2008)]
[Notices]
[Pages 31696-31697]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-12339]
[[Page 31696]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0314]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Recall Regulations
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on FDA's recall regulations and
provides guidance to manufacturers on recall responsibilities.
DATES: Submit written or electronic comments on the collection of
information by August 4, 2008.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Elizabeth Berbakos, Office of the
Chief Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-1482.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
FDA Recall Regulations--21 CFR Part 7 (OMB Control Number 0910-0249)--
Extension
Section 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
371) and 21 CFR part 7, subpart C, set forth the recall regulations
(guidelines) and provides guidance to manufacturers on recall
responsibilities. The guidelines apply to all FDA regulated products
(i.e., food, including animal feed; drugs, including animal drugs;
medical devices, including in vitro diagnostic products; cosmetics; and
biological products intended for human use). These responsibilities
include development of a recall strategy that requires time by the firm
to determine the actions or procedures required to manage the recall
(21 CFR 7.42); providing FDA with complete details of the recall
including reason(s) for the removal or correction, risk evaluation,
quantity produced, distribution information, firm's recall strategy, a
copy of any recall communication(s), and a contact official (21 CFR
7.46); notifying direct accounts of the recall, providing guidance
regarding further distribution, giving instructions as to what to do
with the product, providing recipients with a ready means of reporting
to the recalling firm (21 CFR 7.49); submitting periodic status reports
so that FDA may assess the progress of the recall. Status report
information may be determined by, among other things evaluation return
reply cards, effectiveness checks and product returns (21 CFR 7.53);
and providing the opportunity for a firm to request in writing that FDA
terminate the recall (21 CFR 7.55).
A search of the FDA database was performed to determine the number
of recalls that took place during fiscal year 2007. The resulting
number of recalls from this database search (2,166) is used in
estimating the current annual reporting burden for this report. FDA
estimates the total annual industry burden to collect and provide the
previous information to 216,600 burden hours.
The following table is a summary of the estimated annual burden
hours for recalling firms (manufacturers, processors, and distributors)
to comply with the voluntary reporting requirements of FDA's recall
regulations.
Recognizing that there may be a vast difference in the information
collection and reporting time involved in different recalls of FDA's
regulated products, FDA estimates on average the burden of collection
for recall information to be as follows:
Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours Per
21 CFR Section Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
Recall Strategy 2,166 1 2,166 20 43,320
7.42
----------------------------------------------------------------------------------------------------------------
Firm Initiated 2,166 1 2,166 30 64,980
Recall and
Recall
Communications
7.46 and 7.49
----------------------------------------------------------------------------------------------------------------
[[Page 31697]]
Recall Status 2,166 4 8,664 10 86,640
Reports and
Follow-up 7.53
----------------------------------------------------------------------------------------------------------------
Termination of a 2,166 1 2,166 10 21,660
Recall 7.55(b)
----------------------------------------------------------------------------------------------------------------
Total 216,600
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
The annual reporting burdens are explained as follows:
I. Reporting
A. Recall Strategy
Request firms develop a recall strategy including provision for
public warnings and effectiveness checks. Under this portion of the
collection of information, the agency estimates it will receive 2,166
responses annually.
B. Firm Initiated Recall and Recall Communications
Request firms voluntarily remove or correct foods and drugs (human
or animal), cosmetics, medical devices, and biologicals to immediately
notify the appropriate FDA district office of such actions. The firm is
to provide complete details of the recall reason, risk evaluation,
quantity produced, distribution information, firms' recall strategy and
a contact official as well as requires firms to notify their direct
accounts of the recall and to provide recipients with a ready means of
reporting to the recalling firm. Under these portions of the collection
of information, the agency estimates it will receive 2,166 responses
annually for each.
C. Recall Status Reports
Request that recalling firms provide periodic status reports so the
FDA can ascertain the progress of the recall. This collection of
information will generate approximately 8,664 responses annually.
D. Termination of a Recall
Provide the firms an opportunity to request in writing that FDA end
the recall. The agency estimates it will receive 2,166 responses
annually.
Please note that on January 15, 2008, the FDA Division of Dockets
Management Web site transitioned to the Federal Dockets Management
System (FDMS). FDMS is a Government-wide, electronic docket management
system. Electronic comments or submissions will be accepted by FDA only
through FDMS at https://www.regulations.gov.
Dated: May 27, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-12339 Filed 6-2-08; 8:45 am]
BILLING CODE 4160-01-S